Prevalence Of Chronic Hypercapnia In Severe Chronic Obstructive Pulmonary Disease: Data From The HOmeVent Registry.
chronic obstructive pulmonary disease
hypercapnia
non-invasive ventilation
quality of life
registry
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
accepted:
23
09
2019
entrez:
8
11
2019
pubmed:
7
11
2019
medline:
17
4
2020
Statut:
epublish
Résumé
Non-invasive ventilation (NIV) has been shown to improve survival and quality of life in COPD patients with chronic hypercapnic respiratory failure. However, the proportion of COPD patients with chronic hypercapnia is not yet known and clinical data enabling better identification of patients are scarce. The HOmeVent registry was initiated to determine the prevalence of chronic hypercapnia in COPD in an outpatient setting and to evaluate the predictors of hypercapnia. HOmeVent is a multicenter, prospective, observational, non-interventional patient registry that includes COPD patients in GOLD stage 3 or 4. Eligible patients were identified and enrolled in an outpatient setting during routine clinic visits. Assessments included blood gas analyses, pulmonary function testing and quality of life assessment. Ten outpatient clinics in Germany enrolled 231 COPD patients in the registry (135 in GOLD stage 3 (58%) and 96 in GOLD stage 4 (42%)). Arterial carbon dioxide pressure (PaCO A relevant proportion of COPD patients in GOLD stage 3 and 4 exhibits chronic hypercapnia and might, therefore, be candidates for long-term domiciliary NIV treatment.
Sections du résumé
Background
Non-invasive ventilation (NIV) has been shown to improve survival and quality of life in COPD patients with chronic hypercapnic respiratory failure. However, the proportion of COPD patients with chronic hypercapnia is not yet known and clinical data enabling better identification of patients are scarce. The HOmeVent registry was initiated to determine the prevalence of chronic hypercapnia in COPD in an outpatient setting and to evaluate the predictors of hypercapnia.
Methods
HOmeVent is a multicenter, prospective, observational, non-interventional patient registry that includes COPD patients in GOLD stage 3 or 4. Eligible patients were identified and enrolled in an outpatient setting during routine clinic visits. Assessments included blood gas analyses, pulmonary function testing and quality of life assessment.
Results
Ten outpatient clinics in Germany enrolled 231 COPD patients in the registry (135 in GOLD stage 3 (58%) and 96 in GOLD stage 4 (42%)). Arterial carbon dioxide pressure (PaCO
Conclusion
A relevant proportion of COPD patients in GOLD stage 3 and 4 exhibits chronic hypercapnia and might, therefore, be candidates for long-term domiciliary NIV treatment.
Identifiants
pubmed: 31695357
doi: 10.2147/COPD.S222803
pii: 222803
pmc: PMC6805244
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2377-2384Informations de copyright
© 2019 Dreher et al.
Déclaration de conflit d'intérêts
MD has received speaking and advisor fees from Phillips, Weinmann, and Heinen und Löwenstein, during the conduct of the study. WW has received speaking fees and advisory fees from Weinmann, Vivisol, Heinen und Löwenstein, VitalAire (all in Germany) and from Philips-REspironics (USA) ; in addition, the Cologne study group has received open research grants from Weinmann, Vivisol, Heinen und Löwenstein and VitalAire (all in Germany), and from Philips-Respironics (USA). HW is a paid consultant to ResMed. TF is Chief Executive Officer at the Clinical Research Institute which was in charge of the HOmeVent registry. PCN, DM and A Graml are employees of ResMed. A Gröschel reports personal fees from ResMed, during the conduct of the study. TK and GH have no conflicts of interest to disclose beyond financial support for the HOmeVent registry. The authors report no other conflicts of interest in this work.
Références
Chest. 2007 Jun;131(6):1650-8
pubmed: 17565016
Ann Intern Med. 1994 May 1;120(9):760-70
pubmed: 8147550
J Clin Epidemiol. 2003 Aug;56(8):752-9
pubmed: 12954467
N Engl J Med. 1991 Sep 26;325(13):917-23
pubmed: 1881417
Eur Respir J. 2013 Dec;42(6):1472-83
pubmed: 23722617
Eur Respir Rev. 2019 Mar 14;28(151):null
pubmed: 30872398
Am J Respir Crit Care Med. 1996 Nov;154(5):1310-7
pubmed: 8912741
Thorax. 2009 Jul;64(7):561-6
pubmed: 19213769
Respirology. 2019 Aug;24(8):732-739
pubmed: 30729638
BMJ. 2003 Jan 25;326(7382):185
pubmed: 12543832
N Engl J Med. 2004 Mar 4;350(10):1005-12
pubmed: 14999112
Chest. 2000 Feb;117(2 Suppl):5S-9S
pubmed: 10673466
Eur Respir J. 2005 Jun;25(6):1025-31
pubmed: 15929957
N Engl J Med. 1995 Sep 28;333(13):817-22
pubmed: 7651472
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Lancet Respir Med. 2014 Sep;2(9):698-705
pubmed: 25066329
Am Rev Respir Dis. 1985 Jul;132(1):42-7
pubmed: 4014871
Respiration. 2018;96(2):171-203
pubmed: 29945156
Int J Chron Obstruct Pulmon Dis. 2016 Oct 07;11:2519-2526
pubmed: 27785008
Pneumologie. 2015 Mar;69(3):147-64
pubmed: 25750095
Am J Respir Crit Care Med. 2012 Jan 15;185(2):152-9
pubmed: 22016446
Proc Am Thorac Soc. 2008 Feb 15;5(2):218-25
pubmed: 18250215
Eur Respir J. 2009 Sep;34(3):648-54
pubmed: 19720809
Thorax. 2004 Dec;59(12):1020-5
pubmed: 15563699
Curr Opin Pulm Med. 2012 Mar;18(2):97-103
pubmed: 22262138
Respiration. 2018;96(1):66-97
pubmed: 29945148
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
JAMA. 2017 Jun 6;317(21):2177-2186
pubmed: 28528348